cadenas
  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Solid Tumor

Solid Tumor 24

Trial
    • Phase I-II Study of Vinblastine in combination with Nilotinib in children and adolescents with refractory or recurrent low-grade glioma : A SIOP and ITCC protocol

    • A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

    • Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology

    • Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication : BIOMEDE

    • A Phase I/II, Multicenter, Open-Label, dose‑escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously treated Solid Tumors

    • A phase IB study of crizotinib (Xalcori®) in pediatric malignancies with anaplastic lymphoma kinase (ALK) aberrations

    • A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

    • European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children

    1 - 8 sur 24